Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
November 07, 2023 07:00 ET
|
Mersana Therapeutics, Inc.
Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADCPreparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2...
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
October 31, 2023 16:30 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
October 31, 2023 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Changes in Leadership
September 06, 2023 07:00 ET
|
Mersana Therapeutics, Inc.
Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named...
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
August 08, 2023 08:00 ET
|
Mersana Therapeutics, Inc.
Organization fully focused on product candidates and collaborations based on next-generation ADC platformsCapital resources expected to support current operating plan commitments into 2026 CAMBRIDGE,...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization
July 27, 2023 07:06 ET
|
Mersana Therapeutics, Inc.
UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces expenses to extend cash runway into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE,...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials
June 15, 2023 07:30 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2023 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...